Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc. |
| February 26, 2014 | February 2014 Bond Updates |
|
NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the... |
| View more at: http://www.prnewswire.com/news-releases/nuvilex-comprehensive-analyst-report-answers-vital-questions-for-shareholders-by-brokerbank-securities-inc-247231821.html |
| Related News |
|